[Antiplatelet agents and cardiovascular prevention].
The main contributions of meta-analysis methodology to antiplatelet therapy in the field of cardiovascular prevention are presented with regard to the different sectors of the health system: help with therapeutic information, help in the planning of clinical trials for the pharmaceutical industry and help in decision-making for Health Authorities. The results of meta-analysis of available data concerning aspirin in cardio-vascular prevention are discussed, in an attempt to define optimal daily dose and duration of aspirin treatment.
Barry
S
S
RCTs, Lyon, France.
Mercier
S
S
D001241:Aspirin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D004345:Drug Industry; D011307:Drug Prescriptions; D006801:Humans; D007880:Legislation, Drug; D015201:Meta-Analysis as Topic; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors; D001241:Aspirin